Isles C G, Robertson S, Hill D
Renal Unit, Dumfries and Galloway Royal Infirmary, UK.
QJM. 1999 Mar;92(3):159-67. doi: 10.1093/qjmed/92.3.159.
To evaluate the efficacy and safety of renal artery stents in renovascular disease, we identified 10 descriptive studies containing sufficient information for systematic evaluation. No randomized comparisons of stenting with angioplasty or with surgery were found. Overall, stents were placed in 416 renal arteries in 379 patients, mean age 64 years (range 27-84), 56% male. Of the stenoses, 97% were atheromatous (inter-study range 71-100%), 80% ostial (22-100%) and 31% bilateral (12-87%). The clinical indication for stenting was usually hypertension with or without mild renal impairment. Radiological indications for stenting were: narrowing of > or = 50% (in 9/10 studies) as a result of elastic recoil (58%) or dissection (2%) at the time of angioplasty; restenosis some time after angioplasty (15%); or as a primary procedure (25%). Technical success was reported in 96-100% of procedures. Restenosis (> or = 50% narrowing), evaluated in 312/416 (75%) arteries, generally between 6 and 12 months, was 16% overall. Hypertension was cured by stenting (DBP < or = 90 mmHg on no treatment) in 34/379 (9%) overall and in 34/207 (16%) of those whose renal function was normal initially. Six of 379 (1.6%) patients died within 30 days of stenting, but in only two (0.5%) was death judged to be procedure-related. Complications, other than those which led to dialysis, occurred in 42/379 (13%) patients, one third requiring intervention, ranging from blood transfusion to a surgical bypass procedure. Renal function as judged by serum creatinine concentration (SCC) improved in 26%, stabilized in 48% and deteriorated in 26% of patients whose renal function was impaired initially (SCC > 133 mumol/l). In one study, with average baseline SCC > 200 mumol/l, successful stenting slowed the rate of progression of renal failure when renal function was deteriorating beforehand. Nine of 379 (2.4%) patients, including 7/14 (50%) whose SCC was > or = 400 mumol/l initially, required dialysis after stenting. Stenting should be offered by specialist centres as a secondary procedure for unsuccessful angioplasty, or restenosis following angioplasty, to patients with renovascular disease and uncontrolled hypertension, advancing renal failure or pulmonary oedema.
为评估肾动脉支架在肾血管疾病中的疗效和安全性,我们确定了10项描述性研究,这些研究包含足够的信息用于系统评估。未发现支架置入术与血管成形术或手术的随机对照研究。总体而言,在379例患者的416条肾动脉中置入了支架,患者平均年龄64岁(范围27 - 84岁),男性占56%。在这些狭窄病变中,97%为动脉粥样硬化性(研究间范围71% - 100%),80%为开口处狭窄(22% - 100%),31%为双侧狭窄(12% - 87%)。支架置入术的临床指征通常是伴有或不伴有轻度肾功能损害的高血压。支架置入术的放射学指征为:血管成形术时因弹性回缩(58%)或夹层(2%)导致狭窄≥50%(在9/10的研究中);血管成形术后一段时间出现再狭窄(15%);或作为初始治疗(25%)。96% - 100%的手术报告技术成功。在416条动脉中的312条(75%)进行了再狭窄评估(狭窄≥50%),一般在6至12个月时进行,总体再狭窄率为16%。总体而言,379例患者中有34例(9%)通过支架置入术治愈了高血压(未治疗时舒张压≤90 mmHg),在最初肾功能正常的患者中,207例中有34例(16%)治愈。379例患者中有6例(1.6%)在支架置入术后30天内死亡,但仅2例(0.5%)的死亡被判定与手术相关。除导致透析的并发症外,42/379(13%)的患者出现了其他并发症,其中三分之一需要干预,干预范围从输血到外科搭桥手术。最初肾功能受损(血清肌酐浓度[SCC]>133 μmol/L)的患者中,根据血清肌酐浓度判断,26%的患者肾功能改善,48%的患者稳定,26%的患者恶化。在一项研究中,平均基线SCC>200 μmol/L,当肾功能预先恶化时,成功的支架置入术减缓了肾衰竭的进展速度。379例患者中有9例(2.4%)在支架置入术后需要透析,其中包括最初SCC≥400 μmol/L的14例患者中的7例(50%)。对于肾血管疾病且高血压未得到控制、肾衰竭进展或出现肺水肿的患者,专科中心应将支架置入术作为血管成形术失败或血管成形术后再狭窄的二线治疗方法。